Loading
Life sciences · Journal article
Cell Death and Disease · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Ovarian cancer is a leading cause of gynecological cancer-related mortality, with its immunosuppressive tumor microenvironment (TME) limiting the effectiveness of immune checkpoint inhibitor therapy. Alanyl-tRNA synthetase 1 (AARS1) expression in ovarian cancer has been linked to poor prognosis; however, its immunological role remains unclear. In this study, we generated an Aars1-knockdown ID8 syngeneic mouse model to evaluate the role of AARS1 in vivo. Immune infiltration was assessed using flow cytometry and immunohistochemistry. Multi-omics profiling, including single-cell RNA sequencing (scRNA-seq), Ribo-seq, and ATAC-seq, was used to dissect underlying mechanisms. A small-molecule library screen, molecular dynamics simulations, and functional assays were used to identify compounds targeting AARS1. AARS1 depletion suppressed tumor progression, remodeled the TME, decreased myeloid-derived suppressor cells and tumor-associated macrophages, and increased cytotoxic T-lymphocyte (CTL) infiltration. Mechanistically, AARS1 interacted with NAT10 to regulate ribosomal loading of Irf7 mRNA, thereby attenuating type I interferon (IFN-I) signaling. Screening identified deleobuvir as a potent AARS1-binding molecule that disrupted the AARS1–NAT10–mRNA complex, restored IFN-I signaling, and enhanced antitumor immunity. Targeting AARS1 in ovarian cancer promotes CTL infiltration and sensitizes tumors to antitumor immunity.